BioArctic AB (publ) (BIOA-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has a cash flow conversion efficiency ratio of -0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-41.19 Million ≈ $-4.43 Million USD) by net assets (Skr1.97 Billion ≈ $211.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOA-B equity financing ratio to measure how much of total assets are equity-financed.
BioArctic AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIOA-B cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
BioArctic AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioArctic AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peabody Energy Corp
NYSE:BTU
|
0.008x |
|
Comet Holding AG
SW:COTN
|
0.119x |
|
Zhejiang Orient Holdings Co Ltd
SHG:600120
|
0.049x |
|
Shanghai Tunnel Engineering Co Ltd
SHG:600820
|
0.135x |
|
Shanghai Jin Jiang International Hotels Development Co Ltd A
SHG:600754
|
0.091x |
|
Klaviyo, Inc.
NYSE:KVYO
|
0.078x |
|
NIB Holdings Ltd
AU:NHF
|
0.015x |
|
McGrath RentCorp
NASDAQ:MGRC
|
0.065x |
Annual Cash Flow Conversion Efficiency for BioArctic AB (publ) (2015–2024)
The table below shows the annual cash flow conversion efficiency of BioArctic AB (publ) from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see BioArctic AB (publ) stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr894.94 Million ≈ $96.31 Million |
Skr-316.33 Million ≈ $-34.04 Million |
-0.353x | -219.45% |
| 2023-12-31 | Skr1.05 Billion ≈ $112.63 Million |
Skr309.69 Million ≈ $33.33 Million |
0.296x | +835.38% |
| 2022-12-31 | Skr786.24 Million ≈ $84.61 Million |
Skr-31.64 Million ≈ $-3.40 Million |
-0.040x | +77.41% |
| 2021-12-31 | Skr788.68 Million ≈ $84.87 Million |
Skr-140.46 Million ≈ $-15.12 Million |
-0.178x | -74.98% |
| 2020-12-31 | Skr907.30 Million ≈ $97.64 Million |
Skr-92.34 Million ≈ $-9.94 Million |
-0.102x | -130.32% |
| 2019-12-31 | Skr974.50 Million ≈ $104.87 Million |
Skr327.17 Million ≈ $35.21 Million |
0.336x | +270.79% |
| 2018-12-31 | Skr1.02 Billion ≈ $109.52 Million |
Skr-200.06 Million ≈ $-21.53 Million |
-0.197x | +7.60% |
| 2017-12-31 | Skr636.13 Million ≈ $68.46 Million |
Skr-135.33 Million ≈ $-14.56 Million |
-0.213x | -101.91% |
| 2016-12-31 | Skr60.76 Million ≈ $6.54 Million |
Skr675.13 Million ≈ $72.65 Million |
11.111x | +7421.42% |
| 2015-12-31 | Skr108.28 Million ≈ $11.65 Million |
Skr-16.43 Million ≈ $-1.77 Million |
-0.152x | -- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more